Michael Farbowitz, MD
Ophthalmology · Short Hills, NJNPI 1740276393
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,452 of the $9,434 with a category attached, or 68.4%. It is spread thinly across 24 manufacturers, the largest accounting for just 18.9%. Reporting peaked in 2024 at $3,423 and has fallen 86.1% since, to $475 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $45.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Tarsus Pharmaceuticals, Inc.$2K
- Glaukos Corporation$1K
- AbbVie$937
- Rxsight Inc$857
- Lumenis BE Inc$694
- plus $2K from 18 others
Across 4 payments — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$18K
What the payments were for
- Consulting fees$1,50016%
- Speaking & faculty fees$4945%
- Travel & lodging$97310%
- Food & beverage$6,45268%
- Gifts$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 12 | $1,786 |
| Tarsus Pharmaceuticals, Inc. | 6 | $1,594 |
| Glaukos Corporation | 9 | $1,152 |
| AbbVie(2 entities) | 69 | $937 |
| Rxsight Inc | 12 | $857 |
| Lumenis BE Inc | 2 | $694 |
| Sight Sciences, Inc. | 11 | $693 |
| Alcon | 28 | $524 |
| Ocular Therapeutix, Inc. | 11 | $232 |
| Quidel Corporation | 5 | $156 |
| Sun Pharmaceutical Industries Inc. | 9 | $140 |
| Bausch Health US, LLC | 1 | $102 |
| Bausch & Lomb Americas Inc. | 6 | $92 |
| Dompe US, Inc. | 4 | $85 |
| Oyster Point Pharma, Inc. | 5 | $75 |
| Harrow Eye, LLC | 5 | $72 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Eyevance Pharmaceuticals LLC | 3 | $46 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $30 |
| Novartis | 2 | $26 |
| Travere Therapeutics, Inc. | 1 | $18 |
| Johnson & Johnson Vision Care, Inc. | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$1,500
- Tecnis 1-piece IOL$1,255
- Tecnis 3-piece IOL$1,255
- Tecnis Symphony IOL$1,255
- Tecnis Symphony Toric IOL$1,255
- optilight$694
- RXSIGHT CONTACT LENS$608
- RXSIGHT INJECTOR CARTRIDGE$608
- RXSIGHT INJECTOR HANDPIECE$608
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$608
- LIGHT ADJUSTABLE LENS (LAL)$506
- iDose$460
- Tecnis IOL$241
- OMNI(R) SURGICAL SYSTEM (US)$234
- iStent inject Trabecular Micro-Bypass Stent System$233
- iDoseTR$152
- Tecnis Simplicity$142
- iStent inject W$141
- KXL System$141
- Photrexa$141
How this compares
$9,434 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 93 | $36,295 |
| XdemvyLotilaner | 19 | $35,266 |
| RestasisCyclosporine | 36 | $33,036 |
| VyzultaLatanoprostene Bunod | 48 | $19,054 |
| XiidraLifitegrast | 12 | $13,400 |
| CequaCyclosporine | 16 | $13,096 |
| LumiganBimatoprost | 20 | $12,766 |
| MieboPerfluorohexyloctane/Pf | 13 | $9,586 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $8,184 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $7,131 |
| Cyclosporine | 14 | $6,983 |
| Brinzolamide | 17 | $5,201 |
| Loteprednol Etabonate | 26 | $4,716 |
| Brimonidine Tartrate | 35 | $3,044 |
| Timolol Maleate | 57 | $2,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $937 | $53,98684 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $92 | $42,04073 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $14 | $36,29593 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,594 | $35,26619 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $140 | $13,09616 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $30 | $4,71626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Short Hills
- Baljeet PurewalShort Hills$9K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.